Bristol Myers Squibb gains EU approval for Opdivo combination in lymphoma
Go back to Bristol Myers Squibb gains EU approval for Opdivo combination in lymphoma| Bristol-Myers Squibb (NYSE: BMY) | Delayed: 56.91 +1.31 (2.36%) | |||||
|---|---|---|---|---|---|---|
| Previous Close | $55.60 | 52 Week High | $77.12 | |||
| Open | $55.94 | 52 Week Low | $49.03 | |||
| Day High | $56.96 | P/E | 36.95 | |||
| Day Low | $55.74 | EPS | $1.54 | |||
| Volume | 1,809,881 | |||||
